We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Equities research analysts at StockNews.com initiated coverage on shares of Accelerate Diagnostics (NASDAQ:AXDX – Get Free Report) in a report released on Wednesday. The brokerage set a “hold” rating ...

The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.

On Tuesday, Accelerate Diagnostics' Director, John Patience, made a $314,000 purchase of AXDX, buying 200,000 shares at a cost of $1.57 each. So far Patience is in the green, up about 16.6% on ...

Reveal insider sentiment with alternative data that tracks buy and sell trades made by top managers and company directors.

Accelerate Diagnostics (NASDAQ: AXDX) came out with a quarterly loss of $0.88 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to loss of $1.70 per share a year ago.

BTIG resumed coverage of Accelerate Diagnostics (AXDX) with a Buy rating and $14 price target The company’s position as the leading ...

Elevate your confidence by analyzing investor sentiment and stock portfolio shifts, then make your own decisions.

Option chain shows key data for Accelerate Diagnostics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market ...

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Q3 2024 Earnings Call Transcript November 8, 2024 Operator: Good day, and welcome ...